Loading
Loading
Research Overview
Specialty cognitive peptide blend; components proposed to act across BDNF upregulation, glutamatergic modulation, and neuroprotective signalling pathways to support cognition and neuroplasticity in research settings.
Overview
Nootropic peptide research encompasses compounds studied for their effects on cognitive biology, neurotrophic signalling, neuroplasticity, and neuroprotection in laboratory settings. The preclinical research basis for nootropic peptide formulations draws on studies of individual component compounds in relevant neurological model systems, including primary neuronal cell cultures, brain slice preparations, and behavioural rodent model assays.
Key research themes in nootropic peptide biology include BDNF and NGF signalling pathway modulation, synaptic protein expression and long-term potentiation biology, cholinergic neurotransmitter system research, and hippocampal neurogenesis and plasticity in animal model systems. These biological targets represent the preclinical mechanistic framework within which cognitive support peptide compounds are investigated in laboratory settings.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, adamax — nootropic peptide blend has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Specialty cognitive peptide blend; components proposed to act across BDNF upregulation, glutamatergic modulation, and neuroprotective signalling pathways to support cognition and neuroplasticity in research settings.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
